Study guide
5.3 Agitated-Saline Studies and Intracardiac Shunts
CCI Registered Cardiac Sonographer RCS
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: RCS Orientation and Clinical Context
1.1 RCS Identity, Exam Format, Application, and Retesting 1.2 Clinical History, Symptoms, Indications, and Risk Factors 1.3 Prior Studies, Serial Change, and Cross-Modality Context
2 Chapter 2: Orders, Safety, and Patient Preparation
2.1 Order Verification, Scope, and Protocol Selection 2.2 Sonographer Ergonomics and Staff Safety 2.3 Patient Preparation, Positioning, Consent, Infection Control, and Aftercare
3 Chapter 3: Reporting and 2-D TTE Foundations
3.1 Structured Findings, Significant Results, and Escalation 3.2 Standard 2-D TTE Windows, Views, and Acquisition Sequence 3.3 2-D Measurements, Foreshortening, Image Quality, and QA
4 Chapter 4: M-Mode and Doppler Acquisition
4.1 M-Mode Alignment, Timing, Measurements, and Pitfalls 4.2 Color Doppler Acquisition, Scale, Gain, and Jet Display 4.3 PW and CW Spectral Doppler Acquisition
5 Chapter 5: Advanced Doppler and Contrast
5.1 Tissue Doppler and Hemodynamic Sample Placement 5.2 Ultrasound-Enhancing Agents and LV Opacification 5.3 Agitated-Saline Studies and Intracardiac Shunts
6 Chapter 6: Stress Echocardiography
6.1 Exercise Stress Echo Protocols and Peak Imaging 6.2 Pharmacologic Stress Echo, Dobutamine, and Safety 6.3 Non-Ischemic Stress Echo and Hemodynamic Provocation
7 Chapter 7: TEE, Strain, and 3-D TEE
7.1 Assisting TEE: Preparation, Probe Safety, Views, and Complications 7.2 Strain Acquisition, Tracking Quality, and Reproducibility 7.3 3-D TEE Acquisition, Cropping, Orientation, and Artifacts
8 Chapter 8: 3-D TTE and the Aortic Valve
8.1 3-D TTE Full-Volume Acquisition and Quantitation 8.2 Aortic-Valve Anatomy, Morphology, and Function 8.3 Aortic Stenosis: Velocities, Gradients, Valve Area, and Flow States
9 Chapter 9: Aortic Regurgitation and Mitral Structure
9.1 Aortic Regurgitation Mechanisms and Integrated Severity 9.2 Mitral-Valve Anatomy, Motion, and Mechanisms 9.3 Mitral Stenosis: Planimetry, Gradients, Pressure Half-Time, and Suitability
10 Chapter 10: Mitral and Tricuspid Valve Findings
10.1 Mitral Regurgitation Mechanism, Quantitation, and Severity Integration 10.2 Tricuspid-Valve Anatomy, Structure, and Function 10.3 Tricuspid Stenosis Assessment
11 Chapter 11: Right-Sided Valve Disease
11.1 Tricuspid Regurgitation Mechanism and Severity 11.2 Pulmonic-Valve Anatomy, Structure, and Function 11.3 Pulmonic Stenosis Assessment
12 Chapter 12: Pulmonic Regurgitation and Prosthetic Valves
12.1 Pulmonic Regurgitation Mechanism and Severity 12.2 Normal Mechanical and Bioprosthetic Valve Assessment 12.3 Prosthetic Obstruction, Regurgitation, Thrombosis, and Patient–Prosthesis Mismatch
13 Chapter 13: Endocarditis and Cardiac Chambers
13.1 Valvular Endocarditis, Vegetations, Abscess, and Complications 13.2 LV and LA Size, Geometry, Volumes, Mass, and Function 13.3 RV and RA Size, Pressure, Volume, and Function
14 Chapter 14: Cardiomyopathy Phenotypes and Diastology
14.1 Dilated and Hypertrophic Cardiomyopathies, SAM, and LVOT Obstruction 14.2 Restrictive, Arrhythmogenic, and Stress Cardiomyopathies 14.3 Diastolic Function, Filling Pressure, Grading, and Pitfalls
15 Chapter 15: Systolic Function and Ischemia
15.1 LV Systolic Function, Simpson EF, Regional Motion, and Output 15.2 RV Systolic Function: TAPSE, S-prime, FAC, and Coupling 15.3 Ischemic Heart Disease, Coronary Territories, Stress Response, and Complications
16 Chapter 16: Pericardium and Great Vessels
16.1 Pericardial Effusion, Tamponade, Constriction, and Doppler Physiology 16.2 Great Vessels, Venous Return, and Pulmonary Artery Assessment 16.3 Aortic Root, Aneurysm, Dissection, and Coarctation
17 Chapter 17: Pulmonary Pressure, Masses, and Congenital Recognition
17.1 Pulmonary Hypertension, RAP/PASP Estimation, and RV Consequences 17.2 Cardiac Masses, Thrombus, Tumor, Vegetation, and Mimics 17.3 Adult Recognition of ASD, VSD, PFO, PDA, and Congenital Clues
18 Chapter 18: Devices, Strain, and Hemodynamics
18.1 ICDs, Pacemakers, Occluders, Closure Devices, and Mechanical Support 18.2 Strain Interpretation, Global Longitudinal Strain, and Disease Patterns 18.3 Cardiac Hemodynamics, Bernoulli, Continuity, Stroke Volume, and Shunts
19 Chapter 19: Infiltrative Disease and Physics Foundations
19.1 Amyloid, Sarcoid, and Other Infiltrative Disease Patterns 19.2 Ultrasound Wave Properties, Propagation, Frequency, and Wavelength 19.3 Artifact Recognition: Reverberation, Shadowing, Mirror, Refraction, and Aliasing
20 Chapter 20: Resolution and Doppler Optimization
20.1 Axial/Lateral Resolution, Frame Rate, Depth, Focus, and Trade-Offs 20.2 Spectral Doppler Optimization, Nyquist, Filters, Gain, and Angle 20.3 Color Doppler Optimization, Scale, Priority, Variance, and Gain
21 Chapter 21: 2-D, 3-D, and Contrast Optimization
21.1 2-D Optimization: Frequency, Gain, TGC, Harmonics, Depth, and Focus 21.2 3-D Optimization: Volume Rate, Stitching, Cropping, and Display 21.3 Contrast Optimization: Mechanical Index, Destruction, Replenishment, and Artifacts
5.3 Agitated-Saline Studies and Intracardiac Shunts
Key Takeaways Explain This Topic AI
Agitated saline normally opacifies the right heart; left-heart appearance is evaluated for intracardiac or intrapulmonary right-to-left passage.
A valid study uses a verified venous route, secure lockable preparation system, complete agitation, baseline imaging, dense RA opacification, and a sufficiently long clip.
Left-heart appearance within three cycles favors intracardiac passage, appearance after more than five cycles favors transpulmonary passage, and cycles three through five overlap; a directly visualized septal or pulmonary-vein route outweighs timing alone.
An inadequate injection or provocation cannot support a negative conclusion, and the sonographer documents the pattern without independently diagnosing its cause.
Last updated: July 2026
Agitated saline begins in the right heart
An agitated-saline study creates echogenic microbubbles by vigorously mixing a small, protocol-defined amount of air with sterile saline. These bubbles are generally too large to cross normal pulmonary capillaries, so a good peripheral venous injection densely opacifies the right atrium and ventricle. Appearance in the left heart suggests a right-to-left pathway, either through the heart or pulmonary circulation. This physiology is the opposite of commercial UEA left-ventricular opacification, whose stabilized microspheres are designed to traverse the lungs.
Common adult indications include suspected patent foramen ovale or other interatrial communication, suspected intrapulmonary shunt, and evaluation of anomalous systemic venous drainage such as a persistent left superior vena cava. Verify the order, question, patient, venous access, protocol, and administration authority. ASE's comprehensive TTE guidance lists pregnancy and a known significant right-to-left shunt among contraindications for agitated saline; apply current medical direction and local policy rather than assuming a suspected small PFO and a known large shunt are the same circumstance.
Step Technical goal Adequacy evidence
Baseline view Show RA, RV, LA, LV, and interatrial septum before injection No preexisting bubbles or misleading artifact; clear septal plane
Preparation Use sterile materials, two securely locking syringes and stopcock, and the protocol's saline-air mixture Complete agitation with no visible large air bubble; connections remain secure
Injection and recording Coordinate rapid venous injection with a long harmonic clip beginning before RA arrival Dense, homogeneous RA opacification and continuous recording through potential delayed LA arrival
Provocation Transiently raise RA pressure with an approved Valsalva release, cough, or abdominal compression Leftward septal shift or other protocol evidence that RA pressure exceeded LA pressure
Interpretation support Count cycles from full RA opacification and look for the route of left-heart entry Septal crossing favors intracardiac; pulmonary-vein entry favors transpulmonary passage
Prepare and acquire without shortcuts
The 2019 ASE comprehensive adult TTE protocol describes two 10-mL lockable syringes, a three-way stopcock, 8 to 10 mL saline, and no more than 0.5 mL air. Laboratories may have a specifically approved mixture, sometimes including a small amount of the patient's blood, so follow that protocol rather than improvising. Agitate briskly until the bubbles are fine and uniform; never inject a visible macroscopic air pocket. Locking equipment prevents separation during agitation. Use only a confirmed venous line, never an arterial catheter.
Use an optimized A4C to show the interatrial septum; use subcostal A4C when apical imaging is poor. Use harmonic imaging when helpful. Begin the clip with a bubble-free right atrium, capture injection and full right-heart opacification, and record long enough to detect delayed passage. ASE's comprehensive protocol recommends at least 20 consecutive beats. Annotate injection site, rest or maneuver, and injection number.
At rest, a small PFO may show no right-to-left passage because LA pressure exceeds RA pressure. Rehearse Valsalva before injection: the patient strains, bubbles fill the right atrium, and release transiently raises RA pressure relative to LA. A leftward shift of the interatrial septum supports an effective maneuver. Cough or protocol-approved abdominal compression can help when Valsalva is not feasible. A negative study with weak RA opacification or ineffective provocation is nondiagnostic, not proof that no shunt exists.
Count timing, then confirm the pathway
Count cardiac cycles from dense right-atrial opacification, not from the syringe push. Left-heart appearance within three cycles favors an intracardiac pathway, appearance after more than five cycles favors transpulmonary passage, and cycles three through five form an overlap zone rather than a rigid boundary. Timing is a clue, not an absolute law. Direct visualization of bubbles crossing the interatrial septum strongly supports intracardiac passage, while bubbles entering from a pulmonary vein support a transpulmonary route and outweigh cycle counting alone.
Physiology can blur the boundary. High LA pressure or a poor Valsalva can delay passage through a PFO. A large pulmonary arteriovenous connection can produce relatively early bubbles. Eustachian-valve flow can direct an upper-extremity injection away from the septum, and injection site, cardiac output, respiration, and shunt size affect arrival. Pseudocontrast from stagnant blood and excessive gain can mimic a few bubbles. The sonographer records timing, route, maneuver quality, and limitations for physician interpretation rather than diagnosing PFO or pulmonary AVM from a beat count alone.
- Observed pattern Most defensible technical statement
- Immediate septal crossing after full RA opacification Early right-to-left intracardiac passage is demonstrated
- Delayed LA bubbles visibly entering through pulmonary veins Pattern favors transpulmonary passage
No LA bubbles, dense RA, effective Valsalva, complete recording No right-to-left passage demonstrated under the recorded conditions
No LA bubbles but weak RA opacification or failed maneuver Injection or provocation is inadequate; negative conclusion is unsupported
Safety and documentation complete the study
Explain the procedure and maneuver, protect the IV, use aseptic technique, and watch the patient throughout. Stop for new neurologic symptoms, chest pain, severe dyspnea, syncope, significant rhythm change, or another concerning response; assess, call for help, and follow emergency policy. Preserve relevant images and document the event without independently attributing cause.
The worksheet should record indication, venous site, mixture per protocol, number of injections, imaging view, baseline and provocation conditions, RA opacification quality, cycle timing, observed route, shunt-grade method if the laboratory uses one, limitations, symptoms, and communications. In a stroke evaluation, a negative resting injection followed by early septal crossing only after an effective Valsalva release is not contradictory; it demonstrates pressure-dependent passage. Conversely, delayed bubbles without a visible route require cautious correlation. Technique, timing, anatomy, and physiology together make the result interpretable.
Count from right-atrial opacification
The timing clock starts when the right atrium is densely opacified, not when the syringe is pushed. Record the route whenever possible because direct septal crossing or pulmonary-vein entry is more informative than timing alone.